• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BRCA2 Gene Record

  • Summary
  • Interactions
  • Claims
  • BRCA2 675 Clinically Actionable

    Alternate Names:

    675
    BRCA2, DNA REPAIR ASSOCIATED
    BRCA2
    BRCC2
    BROVCA2
    FACD
    FAD
    FAD1
    FANCD
    FANCD1
    GLM3
    PNCA2
    XRCC11
    600185
    1101
    ENSG00000139618
    OTTHUMG00000017411
    7
    PA25412
    BRCA2 DNA REPAIR ASSOCIATED

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (7 More Sources)

    Gene Categories: Category Details

    CLINICALLY ACTIONABLE

    Publications:

    de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov
    Mo et al., 2016, mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer., Clin. Cancer Res.
    Shen et al., 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency., Clin. Cancer Res.
    Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
    Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
    O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
    Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
    Xu et al., 2017, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours., Nat Commun
    Liu et al., 2014, Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study., Lancet Oncol.
    Mirza et al., 2016, Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer., N. Engl. J. Med.
    Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
    Drew et al., 2016, Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer., Br. J. Cancer
    Shroff RT et al., 2018, Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation., JCO Precis Oncol
    Swisher et al., 2017, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial., Lancet Oncol.
    Stachelek et al., 2015, YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors., Mol. Cancer Res.
    Valiakhmetova A et al., 2020, Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response., Oncologist
    2017 Aug 9, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N Engl J Med
    Gelmon et al., 2011, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study., Lancet Oncol.
    Fong et al., 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers., N. Engl. J. Med.
    Kaufman et al., 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation., J. Clin. Oncol.
    Robson et al., 2017, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N. Engl. J. Med.
    Mateo et al., 2015, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer., N. Engl. J. Med.
    Goff, 2013, Advanced ovarian cancer: what should be the standard of care?, J Gynecol Oncol
    Tutt et al., 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial., Lancet
    Kortmann et al., 2011, Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts., Clin. Cancer Res.
    Shah et al., 1975, Cardiovascular effects of beta-receptor stimulants in healthy volunteers., Indian Heart J
    Akamatsu et al., 1975, Increase in acetyl CoA synthetase activity after phenobarbital treatment., Biochem. Pharmacol.
    Tan et al., 1975, Characteristics of the dephosphorylated form of phosphorylase purified from rat liver and measurement of its activity in crude liver preparations., Biochim. Biophys. Acta
    1991, Thallium scintigraphy., Lancet
    Golan T et al., 2019, Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer., N Engl J Med
    Moore K et al., 2018, Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer., N Engl J Med
    Ledermann J et al., 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial., Lancet Oncol
    de Bono J et al., 2020, Olaparib for Metastatic Castration-Resistant Prostate Cancer., N Engl J Med
    Marshall CH et al., 2019, Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations., Eur Urol
    Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.
    Fogelman DR et al., 2011, Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer., Anticancer Res
    McGonigle et al., 2015, E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling., Oncotarget
    LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
    Dillon et al., 2017, Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei., Mol. Cancer Ther.
  • EVOFOSFAMIDE   BRCA2

    Interaction Score: 4.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    25193512


    Sources:
    JAX-CKB

  • PR-104   BRCA2

    Interaction Score: 4.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    25193512


    Sources:
    JAX-CKB

  • INIPARIB   BRCA2

    Interaction Score: 2.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21508395


    Sources:
    CIViC

  • OLAPARIB   BRCA2

    Interaction Score: 2.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    Response Type sensitive
    Approval Status Preclinical - Pdx

    PMIDs:
    32043779 28792849 21862407 25218906 19553641 25366685 28578601 26510020 23346317 26546619 26116172 20609467 21097693 322 15 75 1682772 31157963 30345884 24882434 32343890 30797618


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

  • VELIPARIB   BRCA2

    Interaction Score: 1.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type prostate cancer
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    29338080 25589624 26842236 26801247


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • QUARFLOXIN   BRCA2

    Interaction Score: 1.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28211448


    Sources:
    CIViC

  • TALAZOPARIB   BRCA2

    Interaction Score: 1.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type decreased response
    Approval Status Phase I

    PMIDs:
    28242752 26546619 23881923


    Sources:
    JAX-CKB CIViC PharmGKB OncoKB

  • NIRAPARIB   BRCA2

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type predicted – sensitive
    Evidence Type Actionable
    Approval Status Phase III

    PMIDs:
    27717299


    Sources:
    ClearityFoundationBiomarkers JAX-CKB PharmGKB OncoKB

  • CERALASERTIB   BRCA2

    Interaction Score: 1.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6738 + Radiotherapy
    Indication/Tumor Type colorectal adenocarcinoma
    Response Type sensitive

    PMIDs:
    28062704


    Sources:
    JAX-CKB

  • 2X-121   BRCA2

    Interaction Score: 1.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26513298


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • PAMIPARIB   BRCA2

    Interaction Score: 0.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • RUCAPARIB   BRCA2

    Interaction Score: 0.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    Response Type predicted – sensitive
    Approval Status FDA approved

    PMIDs:
    26779812 27002934 30051098 27908594


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

  • CHLORAMBUCIL   BRCA2

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25193512


    Sources:
    JAX-CKB

  • TEMOZOLOMIDE   BRCA2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    32043779


    Sources:
    CIViC

  • BERZOSERTIB   BRCA2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + VX-970
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • VINORELBINE   BRCA2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Veliparib + Vinorelbine
    Indication/Tumor Type Her2-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    26801247


    Sources:
    JAX-CKB

  • EVEROLIMUS   BRCA2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus + Talazoparib
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    26546619


    Sources:
    JAX-CKB

  • CEDIRANIB   BRCA2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25218906


    Sources:
    CIViC

  • CISPLATIN   BRCA2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Veliparib + Vinorelbine
    Indication/Tumor Type Her2-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    25193512 26801247 29338080 25847936


    Sources:
    JAX-CKB CIViC

  • ETOPOSIDE   BRCA2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    26116172


    Sources:
    JAX-CKB

  • CARBOPLATIN   BRCA2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Veliparib + Carboplatin
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    25847936


    Sources:
    JAX-CKB CIViC

  • IRINOTECAN   BRCA2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Irinotecan + Veliparib
    Indication/Tumor Type ovarian cancer
    Response Type predicted – sensitive

    PMIDs:
    26842236


    Sources:
    JAX-CKB

  • CYCLOPHOSPHAMIDE   BRCA2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Veliparib + Cyclophosphamide
    Indication/Tumor Type ovarian cancer
    Response Type no benefit

    PMIDs:
    25589624


    Sources:
    JAX-CKB

  • GEMCITABINE   BRCA2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29338080


    Sources:
    CIViC

  • PACLITAXEL   BRCA2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Carboplatin + Paclitaxel + Veliparib
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Ensembl: ENSG00000139618

    • Version: 101_38

    Alternate Names:
    BRCA2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • JAX-CKB: BRCA2

    • Version: 27-September-2017

    Alternate Names:
    675 CKB Entrez Id
    BRCA2 CKB Gene Synonym
    BRCC2 CKB Gene Synonym

    Gene Info:

    Publications:
    Stachelek et al., 2015, YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors., Mol. Cancer Res.
    Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
    McGonigle et al., 2015, E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling., Oncotarget

  • CIViC: BRCA2

    • Version: 14-September-2020

    Alternate Names:
    675 Entrez Gene ID
    7 CIViC Gene ID

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:
    Xu et al., 2017, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours., Nat Commun
    de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov
    Pennington et al., 2014, Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas., Clin. Cancer Res.

  • OncoKB: BRCA2

    • Version: 23-July-2020

    Alternate Names:
    675 OncoKB Entrez Id
    FANCD1 OncoKB Gene Synonym
    BROVCA2 OncoKB Gene Synonym

    Gene Info:

    Publications:

  • PharmGKB: BRCA2

    • Version: 18-August-2020

    Alternate Names:
    PA25412 PharmGKB ID

    Gene Info:

    Publications:

  • Tempus: BRCA2

    • Version: 11-November-2018

    Alternate Names:
    BRCA2 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationBiomarkers: BRCA2

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: BRCA2

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: BRCA2

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: BRCA2

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: BRCA2

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21